HER2-positive gastric or gastroesophageal junction adenocarcinoma

Clinical trials for HER2-positive gastric or gastroesophageal junction adenocarcinoma explained in plain language.

Never miss a new study

Get alerted when new HER2-positive gastric or gastroesophageal junction adenocarcinoma trials appear

Sign up with your email to follow new studies for HER2-positive gastric or gastroesophageal junction adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Can a Two-Drug combo shrink Hard-to-Treat stomach tumors?

Disease control Ongoing

This phase II trial tests whether combining an experimental drug called BL-M07D1 with a PD-1 monoclonal antibody can shrink tumors in people with HER2-positive gastric or gastroesophageal junction cancer that is locally advanced or has spread. Participants receive both drugs by i…

Matched conditions: HER2-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Aug 29, 2026 00:00 UTC

HER2-positive gastric or gastroesophageal junction adenocarcinoma

Get alerted when new HER2-positive gastric or gastroesophageal junction adenocarcinoma trials appear

Can a Two-Drug combo shrink Hard-to-Treat stomach tumors?